Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that University of Iowa Health Care Stead Family ...

A new way of treating heart failure patients at Mercy Hospital Washington has been a major success, according to the doctor ...

Reimbursement rate to increase 397% per day effective January 1, 2025New rate expected to encourage adoption of ultrafiltration therapy in the ...

Nuwellis (NUWE) announces that University of Iowa Health Care Stead Family Children’s Hospital in Iowa City, Iowa, has adopted the ...

SeeMedX Inc. ("SeeMedX") today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug ...

Nuwellis ( NASDAQ:NUWE ), this Minneapolis-based medical device company saw its shares rise by 121.32% today as the US ...

Doctors often recommend that heart patients monitor their fluid intake to avoid overhydration. The key is to strike a balance between staying hydrated and preventing fluid overload. Dehydration can ...

indicated for the treatment of congestion due to fluid overload in adults with chronic heart failure. FUROSCIX is a single-use infused diuretic that can be administered at home by patients and ...

up to 261,895 new shares can be issued upon the exercise of 90,780 share options that are still outstanding under the 'Executive Share Options' plan for staff members and consultants of the Company, ...

Ghent, Belgium, 23 October 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Nuwellis (NASDAQ:NUWE – Get Free Report) is set to announce its earnings results before the market opens on Monday, November ...

Before starting an IV drip, a healthcare professional will assess the patient’s condition and determine the type of solution ...